GlassScriptPhysician profile
Alan Soroka
NPI 1720065428
$15,190.68
in general payments reported to CMS, 2019-2025
43 companies · $2,375 in 2025
The $2,375 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $1,409 · 2021: $2,933 · 2022: $2,419 · 2023: $2,028 · 2024: $2,127 · 2025: $2,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,449 · Education: $80.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,448.70 |
| Education | $80.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,773.57 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $1,263.53 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $1,163.51 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $966.39 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $793.53 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $755.17 | 2021-2025 | |
| Pfizer INC. | $742.66 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $669.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $560.20 | 2019-2023 | |
| Amgen INC. | $485.55 | 2019-2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $426.10 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $421.71 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $388.17 | 2019-2024 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $370.40 | 2024-2025 | Voquezna |
| Abbott Laboratories | $279.75 | 2019-2024 | Freestyle Libre 3 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $234.99 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mdd US Operations, LLC | $183.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.79 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $167.15 | 2021-2024 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.28 | 2023-2024 | Caplyta |
| Merck Sharp & Dohme LLC | $159.66 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $131.01 | 2023-2024 | Gvoke Hypopen |
| Abbvie INC. | $130.77 | 2021-2024 | Qulipta, Ubrelvy |
| Cequr Corporation | $74.86 | 2023 | Cequr Simplicity |
| Amarin Pharma, INC. | $73.60 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $60.22 | 2022-2023 | Livalo, Seglentis |
| Lundbeck LLC | $54.74 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $53.14 | 2025 | Nexletol |
| Azurity Pharmaceuticals, INC. | $51.75 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $50.04 | 2022 | |
| Horizon Therapeutics Plc | $47.79 | 2021 | |
| Eisai INC. | $46.76 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $38.54 | 2024-2025 | Gemtesa |
| Corium, LLC | $37.84 | 2023 | Azstarys |
| Allergan, INC. | $27.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.06 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $26.67 | 2024 | Quviviq |
| Dexcom, INC. | $21.92 | 2022 | |
| Verona Pharma, INC. | $21.19 | 2025 | Ohtuvayre |
| Circassia INC. | $17.41 | 2019 | |
| Corcept Therapeutics | $16.49 | 2025 | Korlym |
| Seqirus USA INC | $14.84 | 2025 | Flucelvax, Fluad |
| Biohaven Pharmaceutical Holding Company LTD. | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Soroka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.